Breast cancer vaccine - Therion Biologics

Drug Profile

Breast cancer vaccine - Therion Biologics

Alternative Names: Breast cancer vaccine NY-ESO-1 - Therion Biologics; CEA vaccine - Therion; HER-2/neu vaccine - Therion; MUC-1 vaccine - Therion; TBC NEU

Latest Information Update: 22 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therion Biologics
  • Developer National Cancer Institute (USA); Therion Biologics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 25 Jun 2001 Phase-I clinical trials for Breast cancer in USA (Injection)
  • 29 Aug 1996 Preclinical development for Breast cancer in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top